SOUTH SAN FRANCISCO—Fluxion Biosciences, a provider ofcellular analysis tools for use in life science research and drug discoveryapplications, announced in December the expansion of its sales and servicenetwork into Asia.
Fluxion said it sold its first BioFlux 1000 system, asolution for running biologically relevant cellular assays under shear flow, tothe China Academy of Chinese Medical Science, which will initially use thesystem for research on inhibition of thrombus formation on endothelial cells.Fluxion also signed a distribution agreement for its BioFlux line with Seoul, Korea-based DI Biotech aswell as a second agreement with Novel Science that covers sales of both theBioFlux and IonFlux platforms, thelatter of which is an automated, high-throughput solution for ion channel drugdiscovery and research, in Japan.
